Filana Therapeutics, Inc.
FLNA
$1.91
-$0.09-4.50%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -81.23% | -77.63% | -66.34% | -15.81% | 9.60% |
| Gross Profit | 81.23% | 77.63% | 66.34% | 15.81% | -9.60% |
| SG&A Expenses | -36.37% | -43.72% | -82.74% | 18.19% | 126.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -67.61% | -62.61% | -79.03% | -5.88% | 29.96% |
| Operating Income | 67.61% | 62.61% | 79.03% | 5.88% | -29.96% |
| Income Before Tax | 54.56% | 61.32% | -818.51% | -193.45% | -31.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 54.56% | 61.32% | -818.51% | -193.45% | -31.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.56% | 61.32% | -818.51% | -193.45% | -31.92% |
| EBIT | 67.61% | 62.61% | 79.03% | 5.88% | -29.96% |
| EBITDA | 68.57% | 62.72% | 79.26% | 5.56% | -30.87% |
| EPS Basic | 54.76% | 61.59% | -787.31% | -183.26% | -15.71% |
| Normalized Basic EPS | 69.19% | 63.05% | -3,583.33% | -182.46% | -16.28% |
| EPS Diluted | 54.67% | 61.59% | -807.69% | -14.07% | -14.60% |
| Normalized Diluted EPS | 69.19% | 63.05% | -3,583.33% | -184.57% | -16.28% |
| Average Basic Shares Outstanding | 0.43% | 0.69% | 4.56% | 12.23% | 14.01% |
| Average Diluted Shares Outstanding | 0.43% | 0.69% | 4.56% | 9.43% | 14.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |